Bilix Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $19.5M

  • Investors
  • 15

Bilix General Information

Description

Developer of PEGylated bilirubin nanoparticles designed to treat ischemia-reperfusion injury by reducing inflammation and oxidative stress. The company offers a nanoparticle-based therapy with demonstrated safety in early trials and a targeted application for cardiac surgery-associated acute kidney injury, enabling pharmaceutical companies, clinicians, and healthcare providers to address organ damage caused by interrupted and restored blood flow, improve surgical outcomes, and reduce the long-term burden of acute kidney injury.

Contact Information

Website
www.bilix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building C, 338 Gwanggyojungang-ro, Suji-gu
  • Suite 604
  • Yongin, Gyeonggi 16942
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Building C, 338 Gwanggyojungang-ro, Suji-gu
  • Suite 604
  • Yongin, Gyeonggi 16942
  • South Korea
+82

Bilix Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bilix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 10-Dec-2025 $19.5M Completed Clinical Trials - Phase 2
6. Later Stage VC 29-Jul-2025 Completed Clinical Trials - Phase 2
5. Accelerator/Incubator 30-Jun-2025 Completed Clinical Trials - Phase 2
4. Accelerator/Incubator 01-Aug-2024 Completed Clinical Trials - Phase 2
3. Accelerator/Incubator Completed Clinical Trials - Phase 2
2. Seed Round 01-Oct-2021 $2.13K $17.7K Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 24-May-2021 $15.6K $15.6K Completed Clinical Trials - Phase 2
To view Bilix’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Bilix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of PEGylated bilirubin nanoparticles designed to treat ischemia-reperfusion injury by reducing inflammation an
Drug Discovery
Yongin, South Korea
12 As of 2025

Southlake, TX
 

Toronto, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bilix Competitors (13)

One of Bilix’s 13 competitors is Renibus Therapeutics, a Venture Capital-Backed company based in Southlake, TX.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Renibus Therapeutics Venture Capital-Backed Southlake, TX
Arch BioPartners Corporation Toronto, Canada
Argenx Formerly VC-backed Zwijnaarde, Belgium
Alloksys Life Sciences Corporate Backed or Acquired Wageningen, Netherlands
Mission Therapeutics Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 5 of 13 competitors. Get the full list »

Bilix Patents

Bilix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024186151-A1 Pharmaceutical composition for preventing or treating ischemia reperfusion injury Inactive 08-Mar-2023
JP-2025525431-A Pharmaceutical composition containing pegylated bilirubin for preventing or treating inflammatory diseases Active 05-Jul-2022
EP-4552640-A1 Pharmaceutical composition for preventing or treating inflammatory diseases comprising pegylated bilirubin Pending 05-Jul-2022
EP-4552640-A4 Pharmaceutical composition for preventing or treating inflammatory diseases comprising pegylated bilirubin Pending 05-Jul-2022
US-20260000600-A1 Pharmaceutical composition for preventing or treating inflammatory diseases comprising pegylated bilirubin Pending 05-Jul-2022 A61K8/86
To view Bilix’s complete patent history, request access »

Bilix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bilix Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds
iM Investment Partners Corporate Venture Capital Minority
BiiG WAVE Accelerator/Incubator
Korea Venture Business Association Accelerator/Incubator
Alpen Route Asset Management Venture Capital Minority
DS Capital Asset Manager Minority
You’re viewing 5 of 15 investors. Get the full list »

Bilix FAQs

  • When was Bilix founded?

    Bilix was founded in 2018.

  • Where is Bilix headquartered?

    Bilix is headquartered in Yongin, South Korea.

  • What is the size of Bilix?

    Bilix has 12 total employees.

  • What industry is Bilix in?

    Bilix’s primary industry is Drug Discovery.

  • Is Bilix a private or public company?

    Bilix is a Private company.

  • What is the current valuation of Bilix?

    The current valuation of Bilix is .

  • What is Bilix’s current revenue?

    The current revenue for Bilix is .

  • How much funding has Bilix raised over time?

    Bilix has raised $29.5M.

  • Who are Bilix’s investors?

    iM Investment Partners, BiiG WAVE, Korea Venture Business Association, Alpen Route Asset Management, and DS Capital are 5 of 15 investors who have invested in Bilix.

  • Who are Bilix’s competitors?

    Renibus Therapeutics, Arch BioPartners, Argenx, Alloksys Life Sciences, and Mission Therapeutics are some of the 13 competitors of Bilix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process